AstraZeneca Capitalizing On Respiratory With Actavis’ Divestiture
This article was originally published in The Pink Sheet Daily
The British pharma is acquiring Actavis’ unwanted respiratory portfolio in a deal that will help AstraZeneca meet the $8 billion in revenues it expects to achieve from its respiratory franchise by 2023. For Actavis, it means unloading a handful of drugs that were underperforming and neglected.
You may also be interested in...
Spain’s Almirall has taken a step back from the hypercompetitive respiratory market through its deal with AstraZeneca. It was becoming too expensive to compete in primary care against big pharma, says company President Jorge Gallardo. Almirall will use proceeds to chart a future course as a specialty pharma focused on dermatology.
Eli Lilly has signed on as a risk-sharing partner with AstraZeneca to develop a BACE inhibitor for Alzheimer’s disease. The deal gives Lilly a mid-stage asset in the challenging field after two of its own candidates failed in late-stage trials.
Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.